Key expectations for long-term treatment include: Weight loss velocity decreases over time, with most reduction occurring in the first 912 months Plateaus lasting 48 weeks are common and do not indicate treatment failure Individual response varies based on genetics, baseline metabolic health, adherence, and lifestyle factors Continued medication use is typically necessary to maintain weight loss Non-scale victoriesimproved mobility, reduced medication burden for comorbidities, better quality of lifeare equally important outcomes Patients should also be aware of potential adverse effects that may affect long-term adherence
A study presented on June 14 at ENDO 2026, the Endocrine Societys annual meeting in Chicago, had researchers use data from the National Institutes of Healths All of Us Research Program, which links participants electronic health records with their Fitbit activity data
GHSR agonists (Ipamorelin) activate the ghrelin receptor pathway
Studies have indicated the potential of Polypodium extract in diminishing melasma pigmentation, including its recurrence, showcasing promising outcomes in clinical settings
The Wegovy pill contains semaglutide, which mimics a natural gut hormone called GLP-1